Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000960 | 1.00 | THRA (0.41) | THRATHRBNPC1RAB9APTPN1 | |
| SCHEMBL6763707 | 0.90 | L3MBTL1 (0.38) | NPC1RAB9ALMNATSHRHPGD | |
| SCHEMBL1623875 | 0.90 | PTGS1 (0.36) | FABP5TSHRHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL6343747 | 0.90 | PTGS1 (0.36) | FABP5TSHRHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL7314603 | 0.86 | PPARG (0.38) | FABP5TSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL6567974 | 0.79 | FABP5 (0.37) | NPC1RAB9AFABP5TSHRHPGD | |
| SCHEMBL2131722 | 0.79 | THRA (0.43) | THRATHRBNPC1RAB9APTPN1 | |
| SCHEMBL3785947 | 0.79 | NPC1 (0.44) | THRATHRBNPC1RAB9APTPN1 | |
| SCHEMBL3367289 | 0.78 | KMT2A (0.45) | THRATHRBNPC1RAB9APTPN1 | |
| SCHEMBL31146900 | 0.78 | KMT2A (0.45) | THRATHRBNPC1RAB9APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015022283-A1 | YAP-TEAD INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| EP-1114061-B1 | FACTOR VIIa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-03-10 | — | — | EP | disclosed |
| US-7393849-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7323457-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070208008-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070191347-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. | 2007-08-16 | — | — | US | disclosed |
| US-7223763-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1423373-B1 | SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040204582-A1 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. | 2004-10-14 | — | — | US | disclosed |
| US-6777577-B2 | ANTICANCER AGENTS; ANTIDIABETIC AGENTS, ANTICHOLESTEROL AGENTS, CARDIOVASCULAR DISORDERS, OSTEOPOROSIS | AVENTIS PHARMACEUTICALS INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1423373-A2 | SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | Aventis Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | ARIAD PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | ARIAD PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2003006444-A2 | SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| US-6287794-B1 | Factor Vlla inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-11 | — | — | US | disclosed |
| EP-1114061-A1 | FACTOR VIIa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2001-07-11 | — | — | EP | disclosed |
| US-6132953-A | PREPARING IN SOLUTION A MIXTURE OF SYNTHONS, INTERMEDIATES OR PRODUCTS WHICH ARE ATTACHED TO SUPPORTS; SEPARATING MIXTURE FROM REACTION MEDIA BY SIZE-EXCLUSION METHOD; FLEXIBILITY OF SOLUTION PHASE SYNTHESIS AND FACILE HOMOGENEOUS PURIFICATION | MERCK & CO., INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000015658-A1 | FACTOR VIIa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208008-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | CHUK, SRC, DSTYK | THRA 2002/4885THRB 1499/4885NPC1 4486/4885 |
| US-20040204582-A1 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | CHUK, SRC, DSTYK | THRA 1974/4885THRB 1512/4885NPC1 4422/4885 |
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | SRC, GRB2, ACP1 | THRA 1481/4885THRB 937/4885NPC1 4321/4885 |
| US-20070191347-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | CHUK, SRC, DSTYK | THRA 2002/4885THRB 1499/4885NPC1 4486/4885 |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | SRC, CTTN, YES1 | THRA 969/4885THRB 793/4885NPC1 3021/4885 |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | SRC, CHUK, DSTYK | THRA 1525/4885THRB 1655/4885NPC1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.